Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)
- Conditions
- COVID-19VaccinesAntibodySARS-CoV-2
- Registration Number
- NCT05084950
- Lead Sponsor
- Centre Scientifique de Monaco
- Brief Summary
Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.
- Detailed Description
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10000
- Participant must live in the Principality of Monaco
- Deliver a written consent to participate to the study
- And/Or Have been infected with SARS-CoV-2
- And/Or Have been, or are about to be, vaccinated against SARS-CoV-2
- None of the above
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Covid-19 Neutralizing Antibodies Measurment 24-month period Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre National de Depistage - Espace Leo Ferre
🇲🇨Monaco, Monaco